MYOFINITY BIOSCIENCES INC
Boston, MA · Biotech · Private
SaCas9 nickase-based gene editing system for removing dystrophin gene duplications to restore full-length dystrophin protein production
- Grants
- $2.7M
- 7 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201820192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Genome-wide CRISPR screen to identify pro-myogenic factors for cell therapy of DMD | $224,725 | |
| Federal grant | Department of Health and Human Services · Phase I · Optimizing membrane repair for the treatment of Duchenne muscular dystrophy | $224,811 | |
| Federal grant | Department of Health and Human Services · Phase I · Translational development of recombinant protein therapeutic for LGMD2B | $259,487 | |
| Federal grant | Department of Health and Human Services · Phase I · Translational development of novel CRISPR approach to treat genomic duplications | $275,651 | |
| Federal grant | Department of Health and Human Services · Phase II · Membrane repair as a therapeutic intervention for treating Becker Muscular Dystrophy | $295,536 | |
| Federal grant | Department of Health and Human Services · Phase II · Membrane repair as a therapeutic intervention for treating Becker Muscular Dystrophy | $811,438 | |
| Federal grant | Department of Health and Human Services · Phase II · Membrane repair as a therapeutic intervention for treating Becker Muscular Dystrophy | $587,105 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1399 | Chemomab | — | — |
| 1400 | KDT, INC | — | — |
| 1401 | HOUSTON PHARMECUTICAL INC | — | — |
| 1402 | MYOFINITY BIOSCIENCES INC | — | — |
| 1403 | PANACISE BIO, INC. | — | — |
| 1404 | On Target Therapeutics, LLC | — | — |
| 1405 | CRYOCRATE LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.